Nothing Special   »   [go: up one dir, main page]

JP2014500722A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500722A5
JP2014500722A5 JP2013538823A JP2013538823A JP2014500722A5 JP 2014500722 A5 JP2014500722 A5 JP 2014500722A5 JP 2013538823 A JP2013538823 A JP 2013538823A JP 2013538823 A JP2013538823 A JP 2013538823A JP 2014500722 A5 JP2014500722 A5 JP 2014500722A5
Authority
JP
Japan
Prior art keywords
glucocerebrosidase
mutant recombinant
glucocerebrosidase protein
recombinant
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538823A
Other languages
Japanese (ja)
Other versions
JP2014500722A (en
JP6073796B2 (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059731 external-priority patent/WO2012064709A2/en
Publication of JP2014500722A publication Critical patent/JP2014500722A/en
Publication of JP2014500722A5 publication Critical patent/JP2014500722A5/ja
Application granted granted Critical
Publication of JP6073796B2 publication Critical patent/JP6073796B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

次の位置：３１６、３１７、３２１および１４５の一つ以上にアミノ酸変異を含む、変異型組換えβ−グルコセレブロシダーゼタンパク質。   A mutant recombinant β-glucocerebrosidase protein comprising an amino acid mutation at one or more of the following positions: 316, 317, 321 and 145. アミノ酸変異Ｆ３１６ＡおよびＬ３１７Ｆを更に含む、請求項１に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 Further comprising an amino acid mutations F316A and L317F, mutant recombinant β- glucocerebrosidase protein of claim 1. 野生型組換えβ−グルコセレブロシダーゼに相対して増加した安定性を有することを特徴とする、請求項２に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 The mutant recombinant β-glucocerebrosidase protein according to claim 2 , characterized by having increased stability relative to wild-type recombinant β-glucocerebrosidase. 増加した安定性が、生理的条件におけるものである、請求項３に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 4. A mutant recombinant β-glucocerebrosidase protein according to claim 3 , wherein the increased stability is at physiological conditions. 増加した安定性が、ほぼ中性ｐＨおよび約３７℃の条件におけるものである、請求項３に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 4. The mutant recombinant β-glucocerebrosidase protein of claim 3 , wherein the increased stability is at about neutral pH and conditions of about 37 ° C. 野生型組換えβ−グルコセレブロシダーゼより少なくとも約２倍長い延長した見掛け半減期を有することを特徴とする、請求項２に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 The mutant recombinant β-glucocerebrosidase protein according to claim 2 , characterized in that it has an extended apparent half-life that is at least about two times longer than wild-type recombinant β-glucocerebrosidase. 延長した見掛け半減期が、ほぼ中性ｐＨおよび約３７℃の条件での約３時間にわたるインキュベーション後に測定される、請求項６に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 7. The mutant recombinant β-glucocerebrosidase protein of claim 6 , wherein the extended apparent half-life is measured after incubation for about 3 hours at about neutral pH and about 37 ° C. 野生型組換えβ−グルコセレブロシダーゼに相対して増加した触媒活性を保持することを特徴とする、請求項２に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 The mutant recombinant β-glucocerebrosidase protein according to claim 2 , characterized in that it retains an increased catalytic activity relative to wild-type recombinant β-glucocerebrosidase. 増加した触媒活性が、ほぼ中性ｐＨおよび約３７℃の条件での約３時間にわたるインキュベーション後に測定される、請求項８に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 9. The mutant recombinant β-glucocerebrosidase protein of claim 8 , wherein the increased catalytic activity is measured after incubation for about 3 hours at about neutral pH and about 37 ° C. 増加した触媒活性が、生理的条件で保持される、請求項８に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質。 The mutant recombinant β-glucocerebrosidase protein of claim 8 , wherein the increased catalytic activity is retained at physiological conditions. 請求項１〜１０のいずれか１項に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質および薬学的に許容しうる担体を含む組成物。A composition comprising the mutant recombinant β-glucocerebrosidase protein according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier. 請求項１〜１０のいずれか１項に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質および薬学的に許容しうる緩衝剤を含む組成物。A composition comprising the mutant recombinant β-glucocerebrosidase protein according to any one of claims 1 to 10 and a pharmaceutically acceptable buffer. 請求項１〜１０のいずれか１項に記載の変異型組換えβ−グルコセレブロシダーゼタンパク質を含む、リソソーム蓄積症を処置するための組成物。A composition for treating a lysosomal storage disease, comprising the mutant recombinant β-glucocerebrosidase protein according to any one of claims 1 to 10.
JP2013538823A 2010-11-08 2011-11-08 Mutant recombinant β-glucocerebrosidase protein with increased stability and increased retention catalytic activity Active JP6073796B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41133110P 2010-11-08 2010-11-08
US61/411,331 2010-11-08
US41218010P 2010-11-10 2010-11-10
US61/412,180 2010-11-10
PCT/US2011/059731 WO2012064709A2 (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017000301A Division JP6457559B2 (en) 2010-11-08 2017-01-05 Mutant recombinant β-glucocerebrosidase protein with increased stability and increased retention catalytic activity

Publications (3)

Publication Number Publication Date
JP2014500722A JP2014500722A (en) 2014-01-16
JP2014500722A5 true JP2014500722A5 (en) 2014-12-25
JP6073796B2 JP6073796B2 (en) 2017-02-01

Family

ID=46051505

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538823A Active JP6073796B2 (en) 2010-11-08 2011-11-08 Mutant recombinant β-glucocerebrosidase protein with increased stability and increased retention catalytic activity
JP2017000301A Active JP6457559B2 (en) 2010-11-08 2017-01-05 Mutant recombinant β-glucocerebrosidase protein with increased stability and increased retention catalytic activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017000301A Active JP6457559B2 (en) 2010-11-08 2017-01-05 Mutant recombinant β-glucocerebrosidase protein with increased stability and increased retention catalytic activity

Country Status (19)

Country Link
US (4) US8962564B2 (en)
EP (2) EP2638152B1 (en)
JP (2) JP6073796B2 (en)
KR (1) KR101901467B1 (en)
CN (2) CN103314105B (en)
BR (1) BR112013011152A2 (en)
CA (1) CA2817011C (en)
CY (1) CY1118843T1 (en)
DK (1) DK2638152T3 (en)
ES (2) ES2604490T3 (en)
HR (1) HRP20161560T1 (en)
HU (1) HUE030932T2 (en)
LT (1) LT2638152T (en)
PL (1) PL2638152T3 (en)
PT (1) PT2638152T (en)
RS (1) RS55405B1 (en)
SI (1) SI2638152T1 (en)
SM (1) SMT201600431B (en)
WO (1) WO2012064709A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127162A1 (en) * 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
WO2021048034A1 (en) 2019-09-09 2021-03-18 F. Hoffmann-La Roche Ag Glucocerebrosidase mutants
JP2023535808A (en) * 2020-07-29 2023-08-21 フリーライン セラピューティクス リミテッド Mutant beta-glucocerebrosidase with improved stability
WO2023145813A1 (en) * 2022-01-31 2023-08-03 株式会社日本触媒 Protein with glucocerebrosidase activity and production method therefor
JPWO2023145814A1 (en) * 2022-01-31 2023-08-03
WO2023145812A1 (en) * 2022-01-31 2023-08-03 株式会社日本触媒 Glycosylated protein having glucocerebrosidase activity
WO2023198661A1 (en) 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
CN118715316A (en) * 2022-10-08 2024-09-27 凌意(杭州)生物科技有限公司 Polynucleotides for treating diseases associated with GCase deficiency

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138686T1 (en) 1988-12-23 1996-06-15 Genzyme Corp CHO CELLS CAPABILITY TO PRODUCE ENZYMATICALLY ACTIVE RECOMBINANT GLUCOCEREBROSIDASE
JPH03503721A (en) * 1988-12-23 1991-08-22 ジェンザイム　コーポレイション Enzymatically active recombinant glucocerebrosidase
JP2002511851A (en) 1997-04-30 2002-04-16 リージェンツ オブ ジ ユニバーシティー オブ ミネソタ Use of recombinant oligonucleobases in vivo to correct hepatocyte genetic lesions in vivo
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
IL135578A0 (en) * 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
CN1342206A (en) * 1998-08-28 2002-03-27 杜克大学 Adenoviruses deleted in IVa2, 100K and/or preterminal protein sequences
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
EP1246915A2 (en) * 1999-12-30 2002-10-09 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
WO2001077307A2 (en) 2000-04-06 2001-10-18 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
WO2002002597A2 (en) 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
WO2004091475A2 (en) 2003-04-16 2004-10-28 Yeda Research And Development Co. Ltd. Gaucher disease drugs and methods of identifying same
WO2005089047A2 (en) * 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
WO2008134628A2 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
CN101743002B (en) * 2007-05-22 2015-11-25 阿米库斯治疗学公司 For the preparation of the new method of isofagomine and its derivant
EP2220218A4 (en) 2007-11-02 2010-12-08 Scripps Research Inst A genetically encoded boronate amino acid
MX2010004807A (en) * 2007-11-02 2010-08-02 Scripss Res Inst Directed evolution using proteins comprising unnatural amino acids.

Similar Documents

Publication Publication Date Title
JP2014500722A5 (en)
JP2016505539A5 (en)
NL300874I2 (en) Elosulfase alpha
MX2024010190A (en) Antisense-induced exon2 inclusion in acid alpha-glucosidase.
HRP20161560T1 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
JP2011528896A5 (en)
NZ702801A (en) Treatment of sanfilippo syndrome type b
CY1118934T1 (en) PREPARATION OF EXTREMELY PHOSPHORLILENED N-ACETYLGACTOZAMINE-6-SULFATHASE ACTIVITY AND USES thereof
JP2012532596A5 (en)
NZ702803A (en) Cns delivery of therapeutic agents
JP2012184234A5 (en)
TW201612167A (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane -2-carboxamides as dipeptidyl peptidase 1 inhibitors
JP2010512795A5 (en)
JP2013231081A5 (en)
WO2012000103A8 (en) Methods of targeting pten mutant diseases and compositions therefor
JP2011136997A5 (en)
JP2014513952A5 (en)
JP2011528897A5 (en)
RU2017143580A (en) IMPROVED SEQUENCE OF URICASES AND TREATMENT METHODS
JP2021505620A5 (en)
JP2014518641A5 (en)
JP2014513123A5 (en)
MX349364B (en) Novel alpha 1-antitrypsin variant, preparation method thereof, and use thereof.
MA34645B1 (en) NEW CRYSTALLINE FORMS
JP2009507474A5 (en)